LITTLE ROCK, Ark.— An execution drug obtained by the Arkansas prison system earlier this month appears to have been made by a subsidiary of Pfizer, even though the pharmaceutical giant has said it doesn't want its drugs to be used in executions. It matches labels submitted to the National Institutes of Health by Hospira, Inc., which Pfizer bought last year. » Read More
Shares of Dow component Merck rare getting a nice little shot in the arm this morning on an upgrade by Dr. Tim Anderson at Sanford C. Bernstein. He's putting an "Outperform" or "Buy" rating on MRK and raising his target price three bucks to $30.
Anyone out there who sees hope in the stock market must be on drugs. And I am: Lipitor and Novasc from Pfizer, Vasotec from Merck, and four other pills, all of which I gobble every day to stop myself from blowing a gasket. So let me say, with some personal pill-popping experience, that this may be a great time to buy drug stocks.
Even better: Events that could push the Dow up another 1,000 points.
Plus, Cramer makes the call on Goldman Sachs, General Electric, Apple, Citigroup and more.
Only on a day like today when it's wall-to-wall Madoff coverage would a $47 billion deal, the second $40-billion-plus deal to be done in four days, struggle to get some airtime.
When a press release crosses the wires or pops into the inbox from a Dow component announcing positive late-stage test results on a cancer drug, you rush to get the headlines on the air as quickly as possible.
The Biotechnology Industry Organization just announced that Sir Elton will be the keynote speaker at the 2009 BIO International Convention in Atlanta, the superstar's American hometown.
On my Thomson Reuters screen I have the stock quotes of a few dozen of the biopharma companies I cover. Lately, when I glance over at it, there's been a lot of red. With today's market rally, there's a whole lotta green. And that's why the quote in red for Genentech kind of sticks out like a sore thumb.
They may have the same name, but America's oldest teenager Dick Clark and Merck's Chairman and CEO Dick Clark appear to have little else in common. One loves the camera, the other not so much.
With cash scarce, credit tight and big drug companies intent on branching into biotechnology themselves, struggling bio-tech start-ups may no longer get second and third chances to succeed from thier investors, the New York Times reports.
New Jersey, where I live and work, is known as "The World's Medicine Chest" or "The Silicon Valley of Pharma."
The president’s budget changes sent stocks tumbling, some undeservedly so.
Yeah, "Deal Or No Deal" has become a bit of a tired cliche, but I think it's totally appropriate in the context of the latest salvo in the Roche-Genentech takeover battle.
Japan and Januvia. No, it's not a country—not even a fictional one—even though it sounds like "Genovia" in "The Princess Diaries." It's a diabetes drug from Merck.
As Pfizer Chairman and CEO Jeff Kindler represents at the White House Healthcare Summit today and tries to make the industry's case against government price controls on prescription drugs, a couple of prominent industry analysts are giving him a little something to smile about.
Forget about mergers and acquisitions (M & A). Think about partnerships and acquisitions or what Leerink Swann, which specializes in healthcare stock coverage, is calling "P & A."
The morning after Genentech's big investor meeting shares of the Swiss drugmaker Roche rebounded in overseas trading and the American Despository Receipts that trade over-the-counter here in the States are following suit.
Chairman and CEO Art Levinson for the first time publicly talked about getting the call from Roche Chairman Franz Humer last July informing him Roche wanted to buy DNA.
This is the first paragraph/short story.
When I wasn't looking the market value of biotech giant DNA surpassed the market cap of the world's biggest drug company, Pfizer.